These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

122 related items for PubMed ID: 6274471

  • 1. A double-blind trial of suloctidil v. placebo in intermittent claudication.
    Jones NA, De Haas H, Zahavi J, Kakkar VV.
    Br J Surg; 1982 Jan; 69(1):38-40. PubMed ID: 6274471
    [Abstract] [Full Text] [Related]

  • 2. Controlled trial of suloctidil in intermittent claudication.
    Verhaeghe R, Van Hoof A, Beyens G.
    J Cardiovasc Pharmacol; 1981 Jan; 3(2):279-86. PubMed ID: 6166799
    [Abstract] [Full Text] [Related]

  • 3. Intermittent claudication: Suloctidil v.s. placebo treatment.
    Holm J, Lindblad L, Scherstén T, Suurkula M.
    Vasa; 1984 Jan; 13(2):175-8. PubMed ID: 6331019
    [No Abstract] [Full Text] [Related]

  • 4. Medical treatment of intermittent claudication: a comparative double-blind study of suloctidil, dihydroergotoxine and placebo.
    Adriaensen H.
    Curr Med Res Opin; 1976 Jan; 4(6):395-401. PubMed ID: 793778
    [Abstract] [Full Text] [Related]

  • 5. [Medical therapy of chronic obstructive arteriopathy of the lower extremities. A controlled clinical study of suloctidil versus xanthinol].
    Spinella G, Majorana M.
    Clin Ter; 1983 Mar 15; 104(5):375-81. PubMed ID: 6303677
    [No Abstract] [Full Text] [Related]

  • 6. A double-blind study comparing suloctidil and placebo in chronic peripheral arteriopathy.
    Gillot P.
    Curr Ther Res Clin Exp; 1976 Nov 15; 20(5):637-44. PubMed ID: 825349
    [No Abstract] [Full Text] [Related]

  • 7. Effect of suloctidil on platelet function in patients with shortened platelet survival time.
    Turpie AG, Gent M, deBoer AC, Giroux M, Kinch D, Butt R, Gunstensen J, Saerens E, Genton E.
    Thromb Res; 1984 Aug 15; 35(4):397-406. PubMed ID: 6091290
    [Abstract] [Full Text] [Related]

  • 8. Double-blind trial of suloctidil versus placebo in moderate to severe mental deterioration.
    Baro F, Malfroid M, Waegemans T, Cox JP.
    Pharmatherapeutica; 1985 Aug 15; 4(6):399-404. PubMed ID: 3001778
    [Abstract] [Full Text] [Related]

  • 9. Clinical and biological activity of the antiplatelet agent suloctidil in treatment of idiopathic recurrent vein thrombosis (I.R.V.T.).
    Moriau M, Col-De Beys C, Pardonge E, Ferrant A.
    Thromb Haemost; 1982 Feb 26; 47(1):27-31. PubMed ID: 6280332
    [Abstract] [Full Text] [Related]

  • 10. Hypocholesterolaemic activity of suloctidil: double-blind, crossover short-term and long-term treatment trial.
    Chieffo C, Postiglione A, Tritto C, Mancini M.
    Curr Med Res Opin; 1984 Feb 26; 9(3):147-52. PubMed ID: 6094103
    [Abstract] [Full Text] [Related]

  • 11. Randomized placebo-controlled, double-blind trial of ketanserin in claudicants. Changes in claudication distance and ankle systolic pressure. PACK Claudication Substudy.
    Circulation; 1989 Dec 26; 80(6):1544-8. PubMed ID: 2688971
    [Abstract] [Full Text] [Related]

  • 12. Ticlopidine in the treatment of intermittent claudication: a 21-month double-blind trial.
    Balsano F, Coccheri S, Libretti A, Nenci GG, Catalano M, Fortunato G, Grasselli S, Violi F, Hellemans H, Vanhove P.
    J Lab Clin Med; 1989 Jul 26; 114(1):84-91. PubMed ID: 2661700
    [Abstract] [Full Text] [Related]

  • 13. Rationale for the use of drugs inhibiting platelet function in claudicating patients with atherosclerotic leg arteries.
    Verstraete M.
    Agents Actions Suppl; 1984 Jul 26; 15():173-87. PubMed ID: 6091423
    [No Abstract] [Full Text] [Related]

  • 14. Clinical and microcirculatory effects of transcutaneous CO2 therapy in intermittent claudication. Randomized double-blind clinical trial with a parallel design.
    Fabry R, Monnet P, Schmidt J, Lusson JR, Carpentier PH, Baguet JC, Dubray C.
    Vasa; 2009 Aug 26; 38(3):213-24. PubMed ID: 19736632
    [Abstract] [Full Text] [Related]

  • 15. Placebo-controlled double-blind trial of ketanserin in treatment of intermittent claudication.
    De Cree J, Leempoels J, Geukens H, Verhaegen H.
    Lancet; 1984 Oct 06; 2(8406):775-9. PubMed ID: 6148522
    [Abstract] [Full Text] [Related]

  • 16. Effects of ethaverine hydrochloride on the walking tolerance of patients with intermittent claudication.
    Trainor FS, Phillips RE, Michie DD, Zellner SR, Hogan L, Chubb JM.
    Angiology; 1986 May 06; 37(5):343-51. PubMed ID: 3521401
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Ketanserin in intermittent claudication. A double-blind placebo-controlled study.
    Clement DL, Duprez D, Van Wassenhove A, Brusselmans F.
    Int Angiol; 1989 May 06; 8(2):92-6. PubMed ID: 2681451
    [Abstract] [Full Text] [Related]

  • 19. A long-term study of policosanol in the treatment of intermittent claudication.
    Castaño G, Más Ferreiro R, Fernández L, Gámez R, Illnait J, Fernández C.
    Angiology; 2001 Feb 06; 52(2):115-25. PubMed ID: 11228084
    [Abstract] [Full Text] [Related]

  • 20. Placebo-controlled, double-blind, two-centre trial of ketanserin in intermittent claudication.
    Bounameaux H, Holditch T, Hellemans H, Berent A, Verhaeghe R.
    Lancet; 1985 Dec 07; 2(8467):1268-71. PubMed ID: 2866336
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.